A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

NCT04670679 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG: ERAS-601
DRUG: Cetuximab
DRUG: Pembrolizumab

Sponsor

Erasca, Inc.